New drug may shield cancer patients from dangerous infection risk

NCT ID NCT07434063

Recruiting now Prevention Sponsor: Hebei Medical University Fourth Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This real-world study looks at whether a drug called mecapegfilgrastim can prevent neutropenia (a low white blood cell count) in cancer patients after chemotherapy, radiation, or immunotherapy. The study will follow 200 adults with solid tumors who are at high or moderate risk of developing neutropenia. Researchers will track how many patients get a fever with low white blood cells and how severe the neutropenia is.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mecapegfilgrastim injection (a drug to boost white blood cells)
What this could lead to: If successful, this could confirm that mecapegfilgrastim effectively prevents dangerous drops in white blood cells after cancer treatment, reducing infection risk.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. Side effects from the drug are possible, and it may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUTROPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neutropenia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUTROPENIA

Contacts and locations

Locations

HebeiMuFH
RECRUITING

Shijiazhuang, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.